PubMed Health⌕ Search

PubMed · 15283577

Stability of the inner polyaniline solid contact layer in all-solid-state K+-selective electrodes based on plasticized poly(vinyl chloride).

Abstract

A simple and powerful method based on UV-visible spectroscopy is presented for studying the stability of the inner electrically conducting polyaniline (PANI) solid contact (SC) layer in all-solid-state ion-selective electrodes (ISE). The influence of the plasticized poly(vinyl chloride) (PVC) membrane (ISM) composition and the pH of the sample solution on the stability of the solid contact is reported. PANI is used as a model compound in this study, but the method presented is universal and can be applied to different types and combinations of SCs and ISMs. It provides a tool for finding the best combination of conducting polymer and ISM for solid contact ISEs. PANI is deposited electrochemically either on glassy carbon or quartz glass covered with a thin layer of tin oxide, and a K+-selective ISM is deposited on top of the PANI layer. The short-term stability of the inner PANI layer is good for all membrane types in buffer solutions with pH 2, 6, and 9, indicating that the outer plasticized PVC membrane hinders the emeraldine salt-emeraldine base transition of the highly pH sensitive PANI layer. The solid contact K+-selective electrodes studied showed a Nernstian response of 58.2 +/- 0.1 mV/log aK. Significant differences are observed in the long-term stability of the inner PANI layer between the different membrane types. This indicates that water uptake of the PVC membrane and its permeability to OH- ions are critical parameters affecting the stability of the PANI layer. The solid contact electrodes based on PANI may require a composition of the PVC membrane different from those typically used in conventional ISEs with an inner solution.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tom Lindfors, Ari Ivaska. 2004-08-01. Stability of the inner polyaniline solid contact layer in all-solid-state K+-selective electrodes based on plasticized poly(vinyl chloride).. https://doi.org/10.1021/ac049439q

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗